{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["King LA"],"pubmed_abstract":["<h4>Background</h4>Vγ9Vδ2 T-cells are antitumor immune effector cells that can detect metabolic dysregulation in cancer cells through phosphoantigen-induced conformational changes in the butyrophilin (BTN) 2A1/3A1 complex. In order to clinically exploit the anticancer properties of Vγ9Vδ2 T-cells, various approaches have been studied including phosphoantigen stimulation, agonistic BTN3A-specific antibodies, adoptive transfer of expanded Vγ9Vδ2 T-cells, and more recently bispecific antibodies. While Vγ9Vδ2 T-cells constitute a sizeable population, typically making up ~1-10% of the total T cell population, lower numbers have been observed with increasing age and in the context of disease.<h4>Methods</h4>We evaluated whether bivalent single domain antibodies (VHHs) that link Vδ2-TCR specific "],"journal":["Frontiers in oncology"],"pagination":["1474007"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11527600"],"repository":["biostudies-literature"],"pubmed_title":["Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion."],"pmcid":["PMC11527600"],"pubmed_authors":["King LA","de Jong M","Lutje Hulsik D","Iglesias-Guimarais V","Veth M","Yousefi P","van Helden PM","van der Vliet HJ","de Gruijl TD"],"additional_accession":[]},"is_claimable":false,"name":"Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion.","description":"<h4>Background</h4>Vγ9Vδ2 T-cells are antitumor immune effector cells that can detect metabolic dysregulation in cancer cells through phosphoantigen-induced conformational changes in the butyrophilin (BTN) 2A1/3A1 complex. In order to clinically exploit the anticancer properties of Vγ9Vδ2 T-cells, various approaches have been studied including phosphoantigen stimulation, agonistic BTN3A-specific antibodies, adoptive transfer of expanded Vγ9Vδ2 T-cells, and more recently bispecific antibodies. While Vγ9Vδ2 T-cells constitute a sizeable population, typically making up ~1-10% of the total T cell population, lower numbers have been observed with increasing age and in the context of disease.<h4>Methods</h4>We evaluated whether bivalent single domain antibodies (VHHs) that link Vδ2-TCR specific ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-05T09:12:36.917Z","creation":"2025-04-05T09:12:36.917Z"},"accession":"S-EPMC11527600","cross_references":{"pubmed":["39493452"],"doi":["10.3389/fonc.2024.1474007"]}}